ArticleOncotarget2017
Disabled cell density sensing leads to dysregulated cholesterol synthesis in glioblastoma.
Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it, 47 citations in OpenAlex.
- Pooled it
- Multilevel metabolic adaptation to exercise training.Communications medicine · 2026Article
- Lomitapide enhances cytotoxic effects of temozolomide in chemotherapy-resistant glioblastoma.JCI insight · 2025Article
- Metabolism of glioblastoma: a review of metabolic adaptations and metabolic therapeutic interventions.Frontiers in oncology · 2025Review
- A multi-layered integrative analysis reveals a cholesterol metabolic program in outer radial glia with implications for human brain evolution.Development (Cambridge, England) · 2024Article
- Discovery and Optimization of N-Arylated Tetracyclic Dicarboximides That Target Primary Glioma Stem-like Cells.Journal of medicinal chemistry · 2024Article
- Metabolic Roles of HIF1, c-Myc, and p53 in Glioma Cells.Metabolites · 2024Review
- Identification of 7-HOCA as a Potential Biomarker in Glioblastoma: Evidence from Genome-Wide Association Study and Clinical Validation.International journal of general medicine · 2024Article
- Serum lipids concentration on prognosis of high-grade glioma.Cancer causes & control : CCC · 2023Article
- The ensured proliferative capacity of myoblast in serum-reduced conditions with Methyl-β-cyclodextrin.Frontiers in cell and developmental biology · 2023Article
- Methionine regulates self-renewal, pluripotency, and cell death of GIC through cholesterol-rRNA axis.BMC cancer · 2022Article
- Astrocyte immunometabolic regulation of the tumour microenvironment drives glioblastoma pathogenicity.Brain : a journal of neurology · 2022Article
- Review of Current Human Genome-Scale Metabolic Models for Brain Cancer and Neurodegenerative Diseases.Cells · 2022Review
- Polyunsaturated Fatty Acid-Enriched Lipid Fingerprint of Glioblastoma Proliferative Regions Is Differentially Regulated According to Glioblastoma Molecular Subtype.International journal of molecular sciences · 2022Article
- Multiple Faces of the Glioblastoma Microenvironment.International journal of molecular sciences · 2022Review
- Metabolic Rewiring in Glioblastoma Cancer:Frontiers in oncology · 2022Review
- Effective Detection and Monitoring of Glioma Using [Biomedicines · 2021Article
- Lipids and Lipid-Processing Pathways in Drug Delivery and Therapeutics.International journal of molecular sciences · 2020Review
- Outer Radial Glia-like Cancer Stem Cells Contribute to Heterogeneity of Glioblastoma.Cell stem cell · 2020Article
- Emerging Roles and Therapeutic Interventions of Aerobic Glycolysis in Glioma.OncoTargets and therapy · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
Abstract
A hallmark of cellular transformation is the evasion of contact-dependent inhibition of growth. To find new therapeutic targets for glioblastoma, we looked for pathways that are inhibited by high cell density in astrocytes but not in glioma cells. Here we report that glioma cells have disabled the normal controls on cholesterol synthesis. At high cell density, astrocytes turn off cholesterol synthesis genes and have low cholesterol levels, but glioma cells keep this pathway on and maintain high cholesterol. Correspondingly, cholesterol pathway upregulation is associated with poor prognosis in glioblastoma patients. Densely-plated glioma cells increase oxygen consumption, aerobic glycolysis, and the pentose phosphate pathway to synthesize cholesterol, resulting in a decrease in reactive oxygen species, TCA cycle intermediates, and ATP. This constitutive cholesterol synthesis is controlled by the cell cycle, as it can be turned off by cyclin-dependent kinase inhibitors and it correlates with disabled cell cycle control though loss of p53 and RB. Finally, glioma cells, but not astrocytes, are sensitive to cholesterol synthesis inhibition downstream of the mevalonate pathway, suggesting that specifically targeting cholesterol synthesis might be an effective treatment for glioblastoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.